Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891863 | 0.80 | KDR (0.41) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL1888436 | 0.79 | ADORA3 (0.37) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL1889933 | 0.78 | CDK2 (0.43) | CDK2CDK4AURKACDK1CDK9 | |
| SCHEMBL1887632 | 0.74 | MAPT (0.51) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2396657 | 0.73 | MEN1 (0.54) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2396778 | 0.73 | PIK3CD (0.68) | MAPTHPGDPIK3CDPIK3CAPIK3CB | |
| SCHEMBL924512 | 0.73 | PIK3CG (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL2397147 | 0.73 | MEN1 (0.61) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2396380 | 0.73 | PIK3CD (0.62) | MEN1KMT2APIK3CDPIK3CAPIK3CB | |
| SCHEMBL2397832 | 0.72 | MEN1 (0.61) | NPC1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| CN-1816549-B | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG | 2010-09-29 | — | — | CN | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101648949-A | inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG CH | 2010-02-17 | — | — | CN | disclosed |
| EP-1622897-B1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| CN-1816549-A | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | NPC1 1629/4885RAB9A 916/4885MEN1 1009/4885 |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | NPC1 1578/4885RAB9A 906/4885MEN1 1083/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | NPC1 1578/4885RAB9A 906/4885MEN1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.